Chlamydia pneumoniae antibody levels before coronary events in the Helsinki Heart Study as measured by different methods

Diagnostic Microbiology and Infectious Disease

Volumn 56, Issue 3, 2006, Pages 233-239

  Paldanius, Mika ^a   Leinonen, Maija ^a   Virkkunen, Hanna ^c   Tenkanen, Leena ^c   Sävykoski, Tiina ^a   Mänttäri, Matti ^d   Saikku, Pekka ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Helsinki Heart Study   (Finland)

^d JORVI HOSPITAL   (Finland)

Author keywords

Chlamydia pneumoniae; Coronary event; EIA; Hypercholesterolemia; IgG and IgA antibodies; Middle aged men; MIF

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR RISK; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME IMMUNOASSAY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION;

ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY COMPLEX; CARDIOVASCULAR DISEASES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DOUBLE-BLIND METHOD; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS;

EID: 33750469694     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.04.007     Document Type: Article

References (32)

1. Arcari C.M., Gaydos C.A., Nieto F.J., Krauss M., and Nelson K.E. Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military: the importance of timing of exposure measurement. Clin. Infect. Dis. 40 (2005) 1123-1130
2. Blessing E., Lin T.M., Campbell L.A., Rosenfeld M.E., Lloyd D., and Kuo C. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice. Infect. Immun. 68 (2000) 4765-4768
3. Bloemenkamp D.G., Mali W.P., Visseren F.L., and van der Graaf Y. Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results?. Am. Heart. J. 145 (2003) 409-417
4. Boman J., and Hammerschlag M.R. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin. Microbiol. Rev. 15 (2002) 1-20
5. Danesh J., Whincup P., Walker M., et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 321 (2000) 208-213
6. Danesh J., Whincup P., Lewington S., et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur. Heart J. 23 (2002) 371-375
7. Dowell S.F., Peeling R.W., Boman J., et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin. Infect. Dis. 33 (2001) 492-503
8. Erkkila L., Laitinen K., Laurila A., Saikku P., and Leinonen M. Experimental Chlamydia pneumoniae infection in NIH/S mice: effect of reinoculation with chlamydial or cell preparation on culture, PCR and histological findings of lung tissue. Vaccine 20 (2002) 2318-2324
9. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317 (1987) 1237-1245
10. Grayston J.T. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J. Infect. Dis. 181 Suppl 3 (2000) S402-S410
11. Grayston J.T., Campbell L.A., Kuo C.C., et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161 (1990) 618-625
12. Halvorsen D.S., Borvik T., Njolstad I., Gutteberg T.J., Vorland L.H., and Hansen J.B. Chlamydia pneumoniae IgA- and IgG antibodies in young survivors of myocardial infarction. A comparison of antibody detection by a microimmunofluorescence test and an enzyme immunoassay. J. Intern. Med. 251 (2002) 142-147
13. Hoymans V.Y., Bosmans J.M., Van Renterghem L., et al. Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis. J. Clin. Microbiol. 41 (2003) 4049-4053
14. Huittinen T., Leinonen M., Tenkanen L., et al. Synergistic effect of persistent Chlamydia pneumoniae infection, autoimmunity, and inflammation on coronary risk. Circulation 107 (2003) 2566-2570
15. Jauhiainen T., Tuomi T., Leinonen M., Kark J.D., and Saikku P. Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test. J. Clin. Microbiol. 32 (1994) 839-840
16. Kontula K., Vuorio A., Turtola H., and Saikku P. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia. Lancet 354 (1999) 46-47
17. Laurila A., Bloigu A., Nayha S., Hassi J., Leinonen M., and Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2910-2913
18. Messmer T.O., Martinez J., Hassouna F., et al. Comparison of two commercial microimmunofluorescence kits and an enzyme immunoassay kit for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae. Clin. Diagn. Lab. Immunol. 8 (2001) 588-592
19. Ossewaarde J.M., Tuuminen T., Boersma W.G., Sandstrom M., Palomaki P., and Boman J. A preliminary evaluation of a new enzyme immunoassay to detect Chlamydia pneumoniae-specific antibodies. J. Microbiol. Methods 43 (2000) 117-125
20. Paldanius M., Bloigu A., Leinonen M., and Saikku P. Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one enzyme immunoassay kit. Clin. Diagn. Lab. Immunol. 10 (2003) 8-12
21. Paldanius M., Bloigu A., Alho M., and Leinonen M. Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland. Clin. Diagn. Lab. Immunol. 12 (2005) 654-659
22. Peeling R.W., Wang S.P., Grayston J.T., et al. Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J. Infect. Dis. 181 Suppl 3 (2000) S426-S429
23. Persson K., and Bowman J. Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae. Clin. Diagn. Lab. Immunol. 7 (2000) 739-744
24. Roivainen M., Viik-Kajander M., Palosuo T., et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 101 (2000) 252-257
25. Saikku P. Seroepidemiology in Chlamydia pneumoniae-atherosclerosis association. Eur. Heart J. 23 (2002) 263-264
26. Saikku P., Leinonen M., Mattila K., et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2 (1988) 983-986
27. Saikku P., Leinonen M., Tenkanen L., et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med. 116 (1992) 273-278
28. Schumacher A., Lerkerod A.B., Seljeflot I., et al. Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals. J. Clin. Microbiol. 39 (2001) 1859-1864
29. Vammen S., Lindholt J.S., Andersen P.L., and Henneberg E.W. Antibodies against Chlamydia pneumoniae predict the need for elective surgical intervention on small abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 22 (2001) 165-168
30. Wald N.J., Law M.R., Morris J.K., Zhou X., Wong Y., and Ward M.E. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 321 (2000) 204-207
31. Wang S.P., and Grayston J.T. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am. J. Ophthalmol. 70 (1970) 367-374
32. Wong Y.K., Sueur J.M., Fall C.H., Orfila J., and Ward M.E. The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae. J. Clin. Pathol. 52 (1999) 99-102